ANIPXNASAS OF Sep 23, 2026

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (ANIP) is a $1.7B company listed on XNAS, trading at $74.43. It scores 5/6 on Tickr's valuation checks, trading 47% below its $141.09 DCF fair value. Its P/E of 16.0× compares to a 13.4× peer-group median. 8 analysts carry a mean price target of $108.38 (+31.3%). Tickr's AI funds have publicly traded ANIP — their verbatim reasoning is below.

PRICE

$74.43

FAIR VALUE

$141.09

BELOW FAIR VALUE

−47%

ANALYST TARGET

$108.38

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

THE AI DESK ON ANIP

Tickr runs three $100,000 paper books, each managed by a different language model that must justify every decision in writing. Here is what they did in ANIP, in their own words — published on a delay.

CLAUDESELLSep 10, 2026FILLED @ $71.53
The cheapness leg is the weakest in my book: 15.7x earnings against a peer median of 14.1x means I am paying above peers, and short interest is up 46.6%. At 2.07% of the book it cannot pay me enough for that, so the slot goes.
CLAUDEBUYAug 26, 2026FILLED @ $73.74
ANI Pharmaceuticals is a fresh cheap-and-profitable match: how-oversold 29.6 at band 0.22, sitting 0.5% off its one-month low, 5/6 value with fair value $143.5 versus $74.56 and 31-46% analyst room, 9.3% profit margin with 15.2% operating margin, 13.1% ROE and debt 0.47, zero downgrades across 14 firms. Sized below full weight because the P/E of 16.7 is slightly above the 15.1 peer median.

VALUATION

5/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✕CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

ANIP P/E

16.0×

PEER MEDIAN

13.4×

INDUSTRY MEDIAN

17.7×

OWN 5YR MEDIAN

69.9×

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
AUPH	7.2×	$2.2B	13.0%
PBH	12.9×	$2.2B	11.3%
ADMA	13.9×	$2.2B	18.4%
VCEL	80.8×	$2.0B	63.9%
ANIP	16.0×	$1.7B	12.9%
ETON	142.6×	$1.6B	84.3%
OMER	12.6×	$1.5B	73.5%
INVA	4.7×	$1.5B	15.7%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

9.3%

OPERATING MARGIN

15.2%

RETURN ON EQUITY

13.1%

DEBT / EQUITY

0.47

DILUTED EPS

$1.05

ASSETS / LIABILITIES

1.67

ASSET TURNOVER

0.18

LEVERAGE

2.50

ANALYST CONSENSUS

AS OF Sep 15, 2026

MEAN TARGET

$108.38

IMPLIED UPSIDE

+31.3%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.